{"organizations": [], "uuid": "30df18fbecc69423b2368adb803545ae8a79914e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 29, "shares": 29, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180420.html", "section_title": "Archive News &amp; Video for Friday, 20 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ucb-acquires-midazolam-nasal-spray/brief-ucb-acquires-midazolam-nasal-spray-from-proximagen-idUSASO0003LD", "country": "US", "domain_rank": 408, "title": "BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.053, "site_type": "news", "published": "2018-04-20T13:18:00.000+03:00", "replies_count": 0, "uuid": "30df18fbecc69423b2368adb803545ae8a79914e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ucb-acquires-midazolam-nasal-spray/brief-ucb-acquires-midazolam-nasal-spray-from-proximagen-idUSASO0003LD", "ord_in_thread": 0, "title": "BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ucb", "sentiment": "negative"}, {"name": "brief-ucb acquires midazolam nasal spray from proximagen", "sentiment": "negative"}, {"name": "ucb sa", "sentiment": "negative"}, {"name": "lam nasal", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 20 (Reuters) - UCB SA:\n* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN\n* UCB WILL MAKE AN UPFRONT CASH PAYMENT OF $150 MILLION * MIDAZOLAM NASAL SPRAY (USL261) COMPLETED PHASE 3 CLINICAL DEVELOPMENT AND IS READY TO BE FILED AS A NEW DRUG APPLICATION (NDA) IN 2018\n* IN ADDITION, PROXIMAGEN IS ELIGIBLE TO RECEIVE CONTINGENT PAYMENTS OF UP TO $220 MILLION BASED ON CERTAIN REGULATORY APPROVAL AND SALES-BASED MILESTONES\n* TRANSACTION IS EXPECTED TO CLOSE IN Q2 OF 2018 * USL261 ALREADY GRANTED ORPHAN DRUG AND FAST TRACK DESIGNATION BY US FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-20T13:18:00.000+03:00", "crawled": "2018-04-21T18:05:11.123+03:00", "highlightTitle": ""}